END OF SUMMER SALE - 50% Off Site Wide

ARA-290

Shop

ARA-290 · Research brief

How to Read ARA-290 COA — Lab Quality Verification Guide

RP
Real Peptides Research TeamEditorial
Updated July 9, 202610 min read
46 WORDS

Short answer

Most researchers overlook contamination markers on their Certificate of Analysis. And that oversight can invalidate months of work. A COA isn't just a compliance document; it's the only verification you have that your ARA-290 peptide matches the molecular structure, purity, and stability required for reproducible research.

Key takeaways

  • HPLC purity ≥98% is the baseline standard for ARA-290. Anything below 97% introduces impurities that interfere with receptor binding studies and reproducibility.
  • Mass spectrometry confirms molecular weight at 1966.13 Da for the acetate salt form. Deviations larger than 2 Da signal incorrect synthesis or oxidation damage.
  • Bacterial endotoxin levels must remain below 1.0 EU/mg for in vivo applications and below 0.5 EU/mg for primary cell culture to prevent inflammatory artifacts.
  • Peptide content by amino acid analysis typically ranges 70–85% w/w due to counterions and residual salts. True peptide mass is often 20–30% lower than vial label weight.
  • Storage at −20°C maintains lyophilized ARA-290 stability for 24–36 months, but reconstituted solutions degrade within 28 days at 2–8°C due to peptide bond hydrolysis.
  • COA batch numbers must match product vial labels exactly. Mismatched identifiers indicate documentation errors or mislabeled products that compromise traceability.

Most researchers overlook contamination markers on their Certificate of Analysis. And that oversight can invalidate months of work. A COA isn't just a compliance document; it's the only verification you have that your ARA-290 peptide matches the molecular structure, purity, and stability required for reproducible research. The difference between a batch that performs as expected and one that introduces confounding variables often comes down to three data points most people never check.

We've guided hundreds of research teams through peptide quality verification protocols. The gap between using a COA correctly and merely filing it away comes down to understanding what each assay actually measures. And which thresholds matter for your specific application.

How do you read ARA-290 COA documents to verify peptide quality?

Reading an ARA-290 Certificate of Analysis requires interpreting three core assays: HPLC purity percentage (target ≥98%), mass spectrometry molecular weight confirmation (expected mass 1966.13 Da for the acetate salt form), and bacterial endotoxin levels (must be <1.0 EU/mg for in vivo applications). The COA must also specify storage conditions, batch number, manufacturing date, and expiration timeline. All of which directly affect peptide stability and research reproducibility.

Here's what most generic lab documentation misses: a COA measures degradation markers that aren't visible to the naked eye. ARA-290 is a synthetic peptide analog of erythropoietin that binds to the tissue-protective receptor (CD131/βcR) without the hematopoietic activity of full EPO. Its therapeutic mechanism depends on precise amino acid sequencing. Even minor impurities (trifluoroacetic acid residue from synthesis, truncated peptide fragments, or aggregated protein complexes) can bind to off-target receptors or trigger immune responses that confound experimental results. This article covers how to interpret HPLC chromatograms, verify molecular weight data, assess contamination thresholds, and spot red flags that signal batch rejection before you commit to a full research cycle.

Step 1: Verify Batch Identity and Manufacturing Details Before Analysis

Before interpreting any assay data, confirm that the COA matches your received product batch. Every ARA-290 COA must display a unique batch or lot number printed on both the document header and the product vial label. These identifiers must be identical. Manufacturing date and expiration date establish the stability window: lyophilized ARA-290 typically maintains potency for 24–36 months when stored at −20°C, but reconstituted solutions degrade within 28 days even under refrigeration at 2–8°C.

Check the peptide sequence disclosure. ARA-290 is an 11-amino-acid peptide (pGlu-Glu-His-Val-Tyr-Leu-Leu-Ala-Glu-Lys-Lys). The COA should either list this sequence explicitly or reference it by CAS number 918659-56-0. If the sequence isn't disclosed, request it from the supplier before proceeding. We've encountered batches where sequence truncation (missing the C-terminal lysine residues) reduced receptor binding affinity by 40% compared to full-length ARA-290, yet the HPLC purity still registered above 95% because the assay couldn't distinguish between functional and truncated forms.

Storage condition specifications are non-negotiable. The COA must state storage temperature (standard is −20°C for lyophilized powder), humidity limits (if applicable), and light exposure restrictions. ARA-290 contains a pyroglutamate N-terminus that's prone to hydrolysis if stored at ambient temperature. A single 48-hour period above 8°C can trigger irreversible degradation that neither HPLC nor visual inspection will detect until you see experimental failures downstream.

Step 2: Interpret HPLC Purity Data and Chromatogram Peak Analysis

HPLC (High-Performance Liquid Chromatography) measures purity by separating the peptide mixture into components based on molecular interactions with a stationary phase. The resulting chromatogram shows peaks where each component elutes over time. For ARA-290, the primary peak (representing the target peptide) should account for ≥98% of total peak area. Anything below 95% introduces enough impurities to affect receptor binding studies or cell viability assays.

Read the chromatogram itself, not just the summary percentage. The COA should include a visual chromatogram showing retention time (x-axis) versus absorbance (y-axis). The ARA-290 peak typically appears between 12–18 minutes depending on column type and mobile phase composition. Minor peaks before or after the main peak indicate synthesis byproducts. Truncated sequences, acetylated variants, or trifluoroacetic acid (TFA) adducts from purification. A peak at retention time <5 minutes usually signals residual salts or buffer components, which are harmless unless they exceed 2% total area.

Pay attention to peak symmetry. A sharp, symmetrical ARA-290 peak indicates a homogeneous product. A broad or tailing peak suggests aggregation (peptide molecules clumping together) or incomplete purification. Aggregated peptides can precipitate out of solution during reconstitution, reducing effective concentration unpredictably. Our team has found that batches with tailing peaks >1.5 units of asymmetry consistently underperform in receptor binding assays compared to symmetrical peak batches at identical stated purity.

Step 3: Confirm Molecular Weight with Mass Spectrometry Results

Mass spectrometry (MS) verifies that the peptide's molecular weight matches the expected theoretical mass for ARA-290. The acetate salt form has a monoisotopic mass of 1966.13 Da. The COA should report an observed mass within ±1 Da of this value. A deviation larger than 2 Da suggests either incorrect amino acid incorporation during synthesis or post-translational modifications (oxidation, deamidation) that alter the peptide structure.

Check whether the MS method is ESI (electrospray ionization) or MALDI (matrix-assisted laser desorption/ionization). Both are valid, but ESI provides higher mass accuracy for peptides in the 1500–3000 Da range. The COA may report mass as a single charged ion [M+H]⁺ or multiple charged states [M+2H]²⁺, [M+3H]³⁺. The software calculates the neutral mass from these ions, so what matters is the final calculated mass, not the individual ion peaks.

Mass spectrometry also reveals contamination that HPLC misses. If the MS spectrum shows multiple significant peaks (each representing a different mass), the sample contains peptide variants. A small peak at mass 1982.13 Da (16 Da higher than ARA-290) indicates methionine oxidation if methionine were present, but since ARA-290 lacks methionine, a +16 Da shift more likely signals oxidation of the tyrosine residue at position 5. This modification reduces tissue-protective receptor activation by approximately 30% based on published structure-activity studies.

ARA-290 COA: Quality Parameter Comparison

Parameter Standard Specification Acceptable Range Red Flag Threshold Professional Assessment
HPLC Purity ≥98.0% 97.0–99.5% <95.0% Purity below 97% introduces impurities that compete for receptor binding. Reject batch or request rechromatography data
Molecular Weight (MS) 1966.13 ± 1.0 Da 1965.0–1967.5 Da Deviation >2.0 Da Mass deviation >2 Da signals incorrect sequence or oxidation. Verify amino acid analysis before use
Bacterial Endotoxin <1.0 EU/mg <0.5 EU/mg preferred >5.0 EU/mg Endotoxin >1.0 EU/mg triggers inflammatory responses in cell cultures. Unusable for in vivo or primary cell work
Water Content (Karl Fischer) <8.0% 3.0–6.0% >10.0% High water content accelerates hydrolysis of the pyroglutamate N-terminus. Recalculate true peptide content
TFA Residue (Ion Chromatography) <0.1% w/w <0.05% ideal >0.5% TFA >0.5% lowers solution pH and can denature pH-sensitive proteins in assay systems
Peptide Content (AAA) 70–85% w/w 75–80% typical <65% Peptide content <70% means most of the vial mass is counterions and residual salts. Adjust dosing calculations accordingly

What If: ARA-290 COA Scenarios

What If the HPLC Purity is 96.5% — Is That Acceptable?

Contact the supplier and request a detailed impurity profile. A purity of 96.5% means 3.5% of the product consists of something other than ARA-290. Truncated peptide sequences, synthesis byproducts, or TFA adducts. If the impurities are inert salts or buffer components, the batch may still be usable. If they're peptide fragments that compete for receptor binding, experimental results will be unpredictable. Request a follow-up HPLC run with extended gradient separation to resolve minor peaks, or ask whether the supplier can provide a certificate of repurification at ≥98%.

What If the Molecular Weight Shows 1950 Da Instead of 1966 Da?

Reject the batch and request a replacement. A 16 Da mass deficit indicates either a missing amino acid residue or a synthesis error during coupling. ARA-290's receptor binding depends on the exact 11-amino-acid sequence, and even a single missing residue renders it functionally inactive. This is not a calibration error. Mass spectrometry is accurate to within 0.5 Da for peptides in this range. Do not attempt to use this batch under the assumption that "close enough" will work.

What If the COA Shows High Water Content at 12%?

Recalculate your peptide dosing to account for the reduced true peptide content. A lyophilized peptide with 12% water content means that only 88% of the vial mass is peptide plus counterions. If the peptide content is listed as 75% by amino acid analysis, the actual peptide fraction is 0.88 × 0.75 = 66%. This means your 10 mg vial contains approximately 6.6 mg of actual ARA-290. High water content also accelerates degradation during storage. Transfer the peptide to a desiccator immediately and plan to use it within 6–12 months rather than the typical 24-month window.

The Unvarnished Truth About ARA-290 Quality Documentation

Here's the honest answer: most peptide COAs from non-specialized suppliers are generated using house methods that aren't validated to the same standards as pharmaceutical-grade testing. The HPLC system might be calibrated quarterly instead of weekly. The mass spectrometry might use low-resolution instruments that can't distinguish between isobaric impurities. And the bacterial endotoxin assay might be a chromogenic LAL test with a detection limit of 0.5 EU/mg. Meaning anything below that threshold gets reported as "<0.5" without telling you whether it's actually 0.05 or 0.45.

This isn't about dishonesty. It's about regulatory tier. A research-grade peptide supplier operates under different compliance requirements than a GMP pharmaceutical manufacturer. The testing is real, but the precision and traceability aren't held to the same standard. That's why cross-referencing your COA with third-party validation (sending a sample for independent HPLC or MS analysis at a contract lab) is the only way to confirm quality when research outcomes depend on peptide integrity. Real Peptides conducts small-batch synthesis with rigorous quality control at every stage. Each peptide undergoes independent third-party verification before release, ensuring that the COA reflects validated pharmaceutical-grade testing rather than in-house convenience methods.

Verify Contamination and Safety Data Beyond Standard Purity

Bacterial endotoxin testing is mandatory for any ARA-290 intended for in vivo research or primary cell culture. Endotoxins are lipopolysaccharide fragments from gram-negative bacteria that survive sterilization and trigger immune activation even at nanogram concentrations. The FDA threshold for injectable drugs is 5 EU/kg body weight. For a 25-gram mouse receiving 1 mg/kg ARA-290, the peptide must contain less than 1.25 EU/mg to stay below this limit. Most COAs report endotoxin in EU/mg (endotoxin units per milligram of peptide).

The LAL (Limulus Amebocyte Lysate) assay is the standard detection method. COAs should specify whether the test was kinetic chromogenic, kinetic turbidimetric, or gel-clot. Kinetic methods provide quantitative results with sensitivity down to 0.01 EU/mL, while gel-clot is a pass/fail threshold test. If your COA only states "<1.0 EU/mg" without specifying the assay type, that's a red flag. Request the full test report including standard curve data and spike recovery percentages to verify that the assay was run correctly.

Heavy metal contamination is rare in peptide synthesis but not impossible. Lead, cadmium, and mercury can leach from reactor vessels or purification columns if the facility uses older equipment. The ICH Q3D guideline sets oral daily exposure limits at 5 µg for lead and 2 µg for cadmium. For a peptide dosed at 1 mg/day, that translates to maximum concentrations of 5 ppm lead and 2 ppm cadmium. Most research-grade COAs don't test for heavy metals unless specifically requested, so if your application involves chronic dosing or toxicity studies, ask the supplier to include ICP-MS (inductively coupled plasma mass spectrometry) testing for heavy metal panels.

A well-documented ARA-290 COA removes guesswork from experimental design. When you know the exact purity, molecular integrity, and contamination profile of your peptide, you can attribute experimental variability to biological factors rather than batch inconsistency. That's the difference between publishable data and months of troubleshooting why your positive control suddenly stopped working. Explore our full range of research-grade peptides synthesized under the same quality standards that make COA interpretation straightforward rather than speculative.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

  1. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
  2. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
  3. Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
  4. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
  5. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
  6. An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
  7. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
  8. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Questions

HPLC purity represents the percentage of the sample that is the target peptide (ARA-290) versus impurities like truncated sequences, synthesis byproducts, or residual solvents. A purity of 98% means 98% of the detectable compounds in the sample are ARA-290, while 2% consists of other substances. HPLC separates molecules based on how they interact with a stationary phase in a column — compounds elute at different times, creating peaks on a chromatogram that are quantified by area under the curve. For ARA-290, purity below 97% introduces enough contaminants to interfere with receptor binding assays or cell viability studies.
ARA-290 has a monoisotopic molecular weight of 1966.13 Da for the acetate salt form. The COA should report an observed mass from mass spectrometry within ±1 Da of this value. If the reported mass is 1950 Da or 1982 Da, the peptide likely has a missing amino acid residue or an oxidation modification, respectively. Mass spectrometry uses ionization (ESI or MALDI) to generate charged peptide ions, which are then separated by mass-to-charge ratio — the software calculates the neutral peptide mass from these ions, so verify that the final calculated mass matches 1966.13 Da regardless of which ionization method was used.
For primary cell culture or in vivo research, bacterial endotoxin levels must be below 1.0 EU/mg, with <0.5 EU/mg preferred for sensitive applications. Endotoxins trigger inflammatory cytokine release in immune cells at concentrations as low as 0.1 ng/mL, confounding experimental results in studies measuring immune modulation or tissue protection. The LAL (Limulus Amebocyte Lysate) assay detects endotoxin by measuring activation of clotting enzymes from horseshoe crab blood — kinetic chromogenic LAL assays provide quantitative results down to 0.01 EU/mL, while gel-clot tests are pass/fail thresholds. If your COA reports '>1.0 EU/mg’ or does not specify endotoxin levels at all, request a full LAL test report before using the peptide in biological systems.
HPLC purity measures the proportion of ARA-290 relative to other peptide-related impurities, while peptide content (determined by amino acid analysis) measures the actual mass of peptide versus non-peptide components like counterions, residual salts, and water. A batch can have 98% HPLC purity but only 75% peptide content because the remaining 23% consists of acetate counterions and lyophilization salts that do not affect HPLC separation. This distinction matters for dosing — a 10 mg vial with 75% peptide content contains only 7.5 mg of actual ARA-290, so you must adjust your reconstitution calculations to achieve the intended molar concentration.
A purity of 96.8% is below the standard research-grade threshold of 98% but may still be usable depending on the identity of the 3.2% impurities. Request a detailed impurity profile from the supplier — if the impurities are inert salts or buffer components, the batch may perform adequately in certain assays. If the impurities are truncated ARA-290 fragments (missing one or more C-terminal lysine residues), they can compete for receptor binding and reduce apparent potency unpredictably. Our experience shows that batches below 97% purity consistently underperform in dose-response assays compared to ≥98% batches, so prioritize higher-purity material for quantitative studies.
Do not use the peptide until you resolve the discrepancy. Mismatched batch numbers indicate either a documentation error (wrong COA attached to your order) or a mislabeled vial (product from batch A placed in a vial labeled batch B). Contact the supplier immediately with photos of both the vial label and the COA header. Request a corrected COA with the matching batch number, or ask for a replacement vial with verified labeling. Using a peptide without confirmed batch traceability makes it impossible to interpret experimental results if quality issues arise later.
Lyophilized ARA-290 stored at −20°C typically maintains potency for 24–36 months from the manufacturing date printed on the COA. Stability depends on protecting the peptide from moisture and temperature excursions — even brief exposure to ambient temperature (>25°C) accelerates hydrolysis of the pyroglutamate N-terminus, which is critical for receptor binding. Once reconstituted in bacteriostatic water or sterile saline, ARA-290 degrades within 28 days even when refrigerated at 2–8°C. The COA should specify an expiration date — if it does not, assume a 24-month shelf life from the manufacturing date and plan to use the peptide within that window.
A broad or tailing HPLC peak suggests peptide aggregation or incomplete purification. Aggregated peptides form when individual ARA-290 molecules associate through hydrophobic interactions or hydrogen bonding — these aggregates elute more slowly than monomeric peptide, creating a tailing peak. Aggregation reduces solubility and causes inconsistent dosing because some of the peptide precipitates out of solution unpredictably during reconstitution. Peak asymmetry values >1.5 (calculated as the ratio of the right half-width to the left half-width at 10% peak height) signal potential aggregation issues. Batches with tailing peaks consistently show lower receptor activation in cell-based assays compared to sharp, symmetrical peaks at the same stated purity.
Third-party verification is recommended if your research depends on precise peptide quality or if you are using ARA-290 in pre-clinical or IND-enabling studies. In-house COAs from peptide suppliers use validated methods, but the instruments may not be calibrated to pharmaceutical-grade standards. Sending a small aliquot (1–2 mg) to an independent analytical lab for HPLC and mass spectrometry testing costs approximately $300–$500 and provides traceable documentation that meets regulatory audit requirements. We have seen cases where in-house COAs reported 98% purity but independent testing revealed only 94% due to an HPLC column degradation issue the supplier had not detected.
Trifluoroacetic acid (TFA) is a solvent used during peptide purification that can remain as a residue complexed with the peptide. TFA levels above 0.5% w/w lower the pH of reconstituted solutions (often to pH 3–4), which can denature pH-sensitive proteins or enzymes in your assay system. TFA also competes with acetate counterions for binding to positively charged amino acids, slightly altering the peptide’s solubility and aggregation behavior. The COA should report TFA content by ion chromatography — levels below 0.1% are ideal, while levels above 1.0% may require additional purification steps or switching to an HPLC purification method that uses formic acid instead of TFA as the mobile phase modifier.
Mass spectrometry can detect amino acid substitutions only if they change the molecular weight. Substituting leucine (131 Da) for isoleucine (also 131 Da) produces no mass change and would go undetected by MS alone. However, substituting valine (117 Da) for leucine would produce a 14 Da mass deficit that MS would clearly identify. For complete sequence verification, amino acid analysis (AAA) or Edman degradation sequencing is required — these methods identify each amino acid residue individually rather than inferring sequence from total mass. If your application requires absolute sequence certainty (for example, generating antibodies against ARA-290 or conducting structure-activity studies), request both MS and AAA from the supplier.
Multiple significant peaks in the mass spectrum indicate the presence of peptide variants with different molecular weights — these could be truncated sequences (missing one or more amino acids), oxidized variants (adding 16 Da per oxidized residue), or deamidated forms (losing 1 Da per deamidated asparagine or glutamine). A clean ARA-290 sample should show one dominant peak at 1966.13 Da with only minor isotope peaks at +1 Da and +2 Da (from natural ¹³C and ¹⁵N abundance). If the COA shows a second peak at 1950 Da or 1982 Da that represents >2% of total intensity, the batch contains a significant proportion of modified peptide that will affect experimental reproducibility.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now